Etamicastat (INNTooltip International Nonproprietary Name; developmental code name BIA 5-453) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which was under development for the treatment of hypertension (high blood pressure) and heart failure but was never marketed.[1][2] The peripheral selectivity of etamicastat is in contrast to the earlier DBH inhibitor nepicastat, which is centrally active and produced associated side effects.[2] Etamicastat was found to reduce blood pressure but not affect heart rate in clinical trials.[2] The development of etamicastat was discontinued by August 2016.[1]

See also

References

  1. ^ a b "Etamicastat". AdisInsight. 27 December 2019. Retrieved 21 October 2024.
  2. ^ a b c Dey SK, Saini M, Prabhakar P, Kundu S (September 2020). "Dopamine β hydroxylase as a potential drug target to combat hypertension". Expert Opin Investig Drugs. 29 (9): 1043–1057. doi:10.1080/13543784.2020.1795830. PMID 32658551.


Allikas: https://en.wikipedia.org/wiki/Etamicastat
No tags for this post.